1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – 2013

Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 110 pages

Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Dong-A Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013” provides data on the Dong-A Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Dong-A Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Dong-A Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Dong-A Pharmaceutical Co., Ltd. - Brief Dong-A Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Dong-A Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Dong-A Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Dong-A Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Dong-A Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Dong-A Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Dong-A Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Dong-A Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Dong-A Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

Dong-A Pharmaceutical Co., Ltd. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Dong-A Pharmaceutical Co., Ltd. Snapshot 8
Dong-A Pharmaceutical Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Dong-A Pharmaceutical Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Dong-A Pharmaceutical Co., Ltd. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products Glance 15
Dong-A Pharmaceutical Co., Ltd. - Late Stage Pipeline 15
Phase III Products/Combination Treatment Modalities 15
Dong-A Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Dong-A Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 18
Pre-Clinical Products/Combination Treatment Modalities 18
Dong-A Pharmaceutical Co., Ltd. - Drug Profiles 19
DA-1229 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
DA-3030 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
DA-3111 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
DA-3131 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
DA-3201 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
DA-3607 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
DA-3803 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
DA-3808 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
DA-3811 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
DA-6034 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DA-6886 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
DA-8031 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
DA-9801 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
darbepoetin alfa 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
exenatide SR 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
interferon beta 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
pegfilgrastim 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
SI-000413 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
somatropin 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Tumor Necrosis Factor Receptor-Hybrid Fc 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
udenafil 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Dong-A Pharmaceutical Co., Ltd. - Pipeline Analysis 44
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products by Therapeutic Class 44
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 45
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action 46
Dong-A Pharmaceutical Co., Ltd. - Recent Pipeline Updates 48
Dong-A Pharmaceutical Co., Ltd. - Dormant Projects 49
Dong-A Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
DA-7867 50
Dong-A Pharmaceutical Co., Ltd. - Company Statement 51
Dong-A Pharmaceutical Co., Ltd. - Locations And Subsidiaries 54
Head Office 54
Other Locations and Subsidiaries 54
Dong-A Pharmaceutical Co., Ltd., Recent Developments 55
Dong-A Pharmaceutical Co., Ltd.- Press Release 55
Feb 07, 2013: Dong-A Pharma's Anti-Tuberculosis Medicine Cycloserine Receives WHO Prequalification Status 55
Oct 12, 2010: Dong-A Launches Zydena For Daily Treatment Of Erectile Dysfunction In Korea 56
Sep 09, 2010: Dong-A Begins Phase III Program Of DA-7218 For Treatment Of Acute Bacterial Skin And Skin Structure Infections 56
Jul 15, 2010: Dong-A Launches MONOTAXEL To Treat Cancer 57
May 20, 2010: Dong-A Begins Phase I Clinical Trial Of DA-8031 For Treatment Of Premature Ejaculation 57
Financial Deals Landscape 58
Dong-A Pharmaceutical Co., Ltd., Deals Summary 58
Dong-A Pharmaceutical Co., Ltd., Pharmaceuticals and Healthcare, Deal Details 61
Partnerships 61
Meiji Seika Pharma Enters Into Co-Development Agreement With Dong-A Pharma 61
Meiji Seika Pharma Enters Into Joint Venture Agreement With Dong-A Pharma 72
Dong-A Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline Korea 74
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 75
GlaxoSmithKline Enters Into Co-Marketing Agreement With Dong-A Pharma For Seretide, Avamys And Vaxar 76
Dong-A Pharma Enters Into Co-Promotion Agreement With Astellas Pharma Korea 78
GlaxoSmithKline Forms Joint Venture With Dong-A Pharma 80
Dong-A Enters Into Agreement With Otsuka Pharma 82
Dong-A Pharma Signs Agreement With Otechestvennye 83
Dong-A Pharma Enters Into Co-Development Agreement With Genexine 85
Licensing Agreements 86
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 86
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 87
Meiji Seika Pharma Enters Into Licensing Agreement With Dong-A Pharma For Zydena 88
Dong-A Pharma Announces Licensing Agreement With Pahang For DA-9701 90
Dong-A Pharma Enters Into Licensing Agreement With Medipost For Cartistem 91
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION 92
Warner Chilcott Amends Licensing Agreement With Dong-A Pharma 93
Abdi Ibrahim Enetrs Into Licensing Agreement With Dong-A Pharma For Zydena 95
Dong-A Pharma Enters Into License Agreement With Sinil Pharma 97
Dong-A Signs License Agreement With Asahi Kasei Pharma 98
Access Pharma Enters Into License Agreement With JCOM And Dong-A 99
Warner Chilcott Enters Into License Agreement With Dong-A 100
Dong-A Pharma Enters Into Licensing Agreement with Trius Therapeutics 102
Asset Transactions 103
Beckman Coulter Acquires Clinical Products Distribution Business From Dong-A Pharma, For $10 Million 103
Acquisition 105
Dong-A Pharma Acquires SAMCHULLY PHARM From SAMCHULLY Group 105
Hanmi Pharma Acquires 9.13% Stake In Dong-A Pharma 107
Hanmi Pharma Acquires 6.27% Stake In Dong-A Pharma 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 110
Disclaimer 110



List of Tables

Dong-A Pharmaceutical Co., Ltd., Key Information 8
Dong-A Pharmaceutical Co., Ltd., Key Facts 8
Dong-A Pharmaceutical Co., Ltd. - Pipeline by Indication, 2013 11
Dong-A Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 13
Dong-A Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 14
Dong-A Pharmaceutical Co., Ltd. - Phase III, 2013 15
Dong-A Pharmaceutical Co., Ltd. - Phase II, 2013 16
Dong-A Pharmaceutical Co., Ltd. - Phase I, 2013 17
Dong-A Pharmaceutical Co., Ltd. - Pre-Clinical, 2013 18
Dong-A Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, 2013 44
Dong-A Pharmaceutical Co., Ltd. - Pipeline By Route of Administration, 2013 45
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 47
Dong-A Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2013 48
Dong-A Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2013 49
Dong-A Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2013 50
Dong-A Pharmaceutical Co., Ltd., Subsidiaries 54
Dong-A Pharmaceutical Co., Ltd., Deals Summary 58
Meiji Seika Pharma Enters Into Co-Development Agreement With Dong-A Pharma 61
Meiji Seika Pharma Enters Into Joint Venture Agreement With Dong-A Pharma 72
Dong-A Pharma Enters Into Co-Promotion Agreement With GlaxoSmithKline Korea 74
Dong-A Pharma Enters Into Co-Marketing Agreement With Bayer Korea 75
GlaxoSmithKline Enters Into Co-Marketing Agreement With Dong-A Pharma For Seretide, Avamys And Vaxar 76
Dong-A Pharma Enters Into Co-Promotion Agreement With Astellas Pharma Korea 78
GlaxoSmithKline Forms Joint Venture With Dong-A Pharma 80
Dong-A Enters Into Agreement With Otsuka Pharma 82
Dong-A Pharma Signs Agreement With Otechestvennye 83
Dong-A Pharma Enters Into Co-Development Agreement With Genexine 85
Dong-A Pharma Enters Into Licensing Agreement With Alkem Labs For DA-1229 86
Luye Pharma Group Enters Into Licensing Agreement With Dong-A Pharma For DA-1229 87
Meiji Seika Pharma Enters Into Licensing Agreement With Dong-A Pharma For Zydena 88
Dong-A Pharma Announces Licensing Agreement With Pahang For DA-9701 90
Dong-A Pharma Enters Into Licensing Agreement With Medipost For Cartistem 91
Dong-A Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For TALION 92
Warner Chilcott Amends Licensing Agreement With Dong-A Pharma 93
Abdi Ibrahim Enetrs Into Licensing Agreement With Dong-A Pharma For Zydena 95
Dong-A Pharma Enters Into License Agreement With Sinil Pharma 97
Dong-A Signs License Agreement With Asahi Kasei Pharma 98
Access Pharma Enters Into License Agreement With JCOM And Dong-A 99
Warner Chilcott Enters Into License Agreement With Dong-A 100
Dong-A Pharma Enters Into Licensing Agreement with Trius Therapeutics 102
Beckman Coulter Acquires Clinical Products Distribution Business From Dong-A Pharma, For $10 Million 103
Dong-A Pharma Acquires SAMCHULLY PHARM From SAMCHULLY Group 105
Hanmi Pharma Acquires 9.13% Stake In Dong-A Pharma 107
Hanmi Pharma Acquires 6.27% Stake In Dong-A Pharma 108



List of Figures

Dong-A Pharmaceutical Co., Ltd. - Pipeline by Indication, 2013 11
Dong-A Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2013 13
Dong-A Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2013 14
Dong-A Pharmaceutical Co., Ltd. - Pipeline By Route of Administration, 2013 45
Dong-A Pharmaceutical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 46

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.